Aplastic Anemia

Slide 1 · Aplastic Anemia

Primary hematopoietic marrow failure

The defining syndrome combines reduced marrow production with pancytopenia.

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Define aplastic anemia and explain its multi-lineage consequences.

Distinguish acquired exposures, immune suppression, and inherited stem-cell defects.

Recognize marrow morphology, clinical manifestations, and diagnostic contrasts.

Relate immune and stem-cell mechanisms to the two major therapeutic approaches.

Slide 3 · Aplastic anemia is a syndrome, not one etiology

Chronic primary hematopoietic failure + pancytopenia

Autoimmune suppression is suspected in most patients; Stem-cell defects also contribute.

Slide 4 · Stem-cell failure produces three peripheral deficits

Multipotent hematopoietic stem cell

Erythroid cells

Anemia

Myeloid cells

Neutropenia

Megakaryocytes

Thrombocytopenia

Schematic lineage overview; The shared stem-cell defect explains simultaneous cytopenias.

Slide 5 · Pancytopenia: Three clinically different losses

Anemia

Loss of red-cell output reduces oxygen-carrying capacity.

Neutropenia

Loss of neutrophil production impairs defence against infections.

Thrombocytopenia

Loss of platelet production increases mucocutaneous bleeding.

A single marrow lesion can therefore produce weakness, infection, and bleeding.

Slide 6 · Marrow failure versus isolated erythroid suppression

Aplastic anemia

Pure red cell aplasia

Hematopoietic failure involves multiple cell lineages.

Erythroid progenitors are selectively suppressed.

Pancytopenia develops as production falls.

Other hematopoietic lineages are comparatively preserved.

Biopsy shows marked overall hypocellularity.

The pattern of cytopenia directs the diagnosis.

Slide 7 · Occurrence and tempo

Aplastic anemia can affect individuals of either sex and any age.

The clinical onset is often insidious rather than abrupt.

A predominant early cytopenia may shape presentation.

Over time, all three cell lines typically become depressed.

Slide 8 · The core clinicopathologic sequence

Hematopoietic stem-cell injury / suppression

Progressive loss of progenitor production

Hypocellular marrow with pancytopenia

Anemia, infection, bleeding

The marrow biopsy connects the blood-count abnormalities to primary failure of production.

Slide 9 · Etiologic framework

Two non-exclusive paths can converge on hematopoietic failure

Aplastic anemia

Acquired forms

Inherited forms

Idiopathic/immune-associated; Chemicals, drugs, infection, irradiation

DNA-repair defects and telomere-maintenance disorders

Failure of marrow hematopoiesis

Slide 10 · Idiopathic cases predominate

~65%

That an initiating factor cannot be identified in about two-thirds of cases.

“Idiopathic” means unrecognized initiator; It does not establish absence of immune injury.

Slide 11 · Exposure-related aplasia has different response patterns

Dose-related injury

Greater exposure to marrow-suppressing agents can produce predictable toxicity.

Idiosyncratic reaction

Severe aplasia may follow an exposure that usually causes little suppression.

An adverse exposure history cannot be interpreted from dose alone.

Slide 12 · Dose-related chemical and drug injury

Many anticancer chemotherapies can suppress the marrow in a dose-related manner.

Alkylating agents and antimetabolites are listed associations.

Benzene is a classic organic solvent linked to marrow suppression.

Dose-related suppression by some agents as reversible.

Slide 13 · Idiosyncratic drug-associated aplasia

Aplastic anemia can occur unexpectedly after drugs with little routine marrow toxicity.

Chloramphenicol, gold salts, and carbamazepine among implicated agents.

Phenylbutazone, penicillamine, and certain arsenicals also appear in the source table.

The response is not predicted reliably by ordinary drug exposure.

Slide 14 · Chloramphenicol illustrates two distinct associations

Listed under dose-related and idiosyncratic chemical agents

Distinguish general pharmacologic marrow suppression from an unusual persistent failure syndrome.

Slide 15 · Benzene: Environmental marrow-toxic exposure

Exposure to an organic solvent

Toxic insult to hematopoietic tissue

Reduced output of marrow progenitors

Possible pancytopenia

Benzene is classified with dose-related chemical exposures.

Slide 16 · Post-hepatitis aplastic anemia

~5%

Viral hepatitis with approximately 5% of aplastic anemia cases.

Why only some infected individuals develop persistent aplasia remains unclear.

Slide 17 · Other viral associations in the source

Cytomegalovirus

Listed among infections associated with persistent marrow aplasia.

Epstein-Barr virus

Listed among viral infections associated with the syndrome.

Varicella-zoster virus

Herpes zoster is also included among the source associations.

Association does not define a single known viral pathogenesis.

Slide 18 · Whole-body irradiation can injure stem cells

Therapeutic or accidental irradiation

Dose-dependent injury to stem cells

Loss of functional progenitor compartment

Marrow aplasia

Nuclear-accident and therapeutic exposures as examples.

Slide 19 · Acquired and inherited disease differ in clinical clues

Acquired disease

Inherited disease

No family history or congenital abnormalities required.

Marrow failure may reflect failure of DNA repair.

Potential relation to drugs, irradiation or viral illness.

Some cases are associated with congenital anomalies.

A substantial fraction has no identifiable inciting exposure.

Telomerase defects can also present in adults.

Slide 20 · Fanconi anemia: DNA repair failure

Inherited defect in a DNA-repair complex

Accumulation of unrepaired genomic injury

Hematopoietic stem-cell vulnerability

Early marrow hypofunction

Fanconi anemia as a rare autosomal recessive disorder.

Slide 21 · Fanconi anemia: Congenital associations

Bone abnormalities

Thumb or radial anomalies are highlighted.

Renal anomalies

Kidney hypoplasia may accompany marrow hypofunction.

Splenic anomalies

Spleen hypoplasia is another described feature.

These associations support a syndromic form of inherited marrow failure.

Slide 22 · Adult-onset disease may involve telomerase

5–10%

Inherited telomerase defects in this proportion of adult-onset aplastic anemia.

This statistic is a textbook estimate, not a diagnostic screening threshold.

Slide 23 · Telomerase deficiency: Stem-cell exhaustion

Impaired telomere maintenance

Reduced replicative reserve

Progressive stem-cell exhaustion

Hypocellular hematopoietic marrow

This causal model is proposed as a mechanistic explanation.

Slide 24 · Short telomeres are not equivalent to telomerase mutations

Up to ½

Abnormally short telomeres are reported in marrow cells of as many as half of affected individuals.

Shortening may reflect unrecognized defects or excessive stem-cell replication.

Slide 25 · Two pathogenesis models are not mutually exclusive

Two non-exclusive paths can converge on hematopoietic failure

Damaged hematopoietic stem-cell compartment

Extrinsic immune suppression

Intrinsic stem-cell dysfunction

Autoreactive T cells suppress and eliminate progenitors

Acquired or inherited defects reduce proliferation and differentiation

Markedly reduced marrow output

Slide 26 · Proposed immune-mediated pathogenesis

1

Drug, infectious or unknown insult changes the stem-cell compartment.

2

Altered cells may display antigens recognized by T cells.

3

Activated T cells release inhibitory cytokines.

4

Progenitor apoptosis and suppressed hematopoiesis follow.

Antigens that trigger the autoreactive response remain incompletely identified.

Slide 27 · Immune trigger: Antigenically altered stem cells

Injury may create immunologically recognizable neoantigens

This is a mechanistic proposal, not identification of a universal aplastic-anemia autoantigen.

Slide 28 · Activated Th1 cells can inhibit marrow progenitors

Autoreactive T-cell activation

Type 1 helper T-cell response

Cytokines including interferon-γ

Progenitor suppression and death

IFN-γ-mediated effects in the proposed immune model.

Slide 29 · Interferon-γ and apoptosis pathways

IFN-γ exposure is linked to expression of pro-death genes in stem cells

Residual stem cells from aplastic marrows show increased expression of apoptosis-related genes.

Slide 30 · Gene-expression evidence supports immune injury

Observation in aplastic marrow

Experimental parallel

Apoptosis and death-pathway genes are upregulated in residual stem cells.

Comparable gene activation occurs in normal stem cells exposed to IFN-γ.

The remaining progenitor pool is profoundly depleted.

The similarity supports—but does not prove—causation.

Slide 31 · Response to immunosuppression supports an immune component

60–70%

Improvement in marrow function in this proportion of patients treated with antithymocyte globulin and related immunosuppressants.

An observed response rate is not proof that every case has the same autoimmune mechanism.

Slide 32 · Why immunosuppressants can restore hematopoiesis

Suppression of autoreactive T-cell clones

Reduced immune pressure on residual stem cells

Greater survival of hematopoietic progenitors

Improvement in peripheral blood counts

This is the mechanism proposed, not a guaranteed response in all patients.

Slide 33 · Autoreactive antigens remain incompletely defined

Robbins does not identify a single autoantigen shared by all cases.

Immune attack may follow diverse stem-cell or environmental insults.

GPI-linked proteins are proposed targets in a subset.

Mechanistic heterogeneity is consistent with variable response to therapy.

Slide 34 · Why aplastic anemia and PNH can coexist

Aplastic anemia

Paroxysmal nocturnal hemoglobinuria

Autoimmune selection pressure is proposed in many patients.

A somatic PIGA mutation creates cells deficient in GPI-linked proteins.

Residual stem cells may be subjected to antigen-directed attack.

GPI-deficient clones may gain a selective advantage under immune pressure.

Slide 35 · Proposed immune selection of a PNH clone

Marrow contains normal and PIGA-mutant stem cells

Immune attack selects against susceptible cells

A GPI-deficient clone is relatively spared

PNH clone may expand

This is an explanatory hypothesis; Do not equate all aplastic anemia with PNH.

Slide 36 · Intrinsic pathogenesis begins within the stem cell

The progenitor itself loses proliferative or differentiation capacity

Stem-cell injury may result from acquired genetic lesions or defects in genomic maintenance.

Slide 37 · Evidence for intrinsic stem-cell defects

Chromosomal changes

Karyotypic abnormalities can be detected in some cases.

Somatic mutations

Acquired mutations in cancer-associated genes occur in many patients.

Telomere abnormalities

Short telomeres support impaired stem-cell replicative reserve.

Slide 38 · Intrinsic damage can progress to clonal disease

Genetic injury within stem cells

A clone with abnormal growth potential

Additional clonal evolution in some cases

Myelodysplastic neoplasm or acute myeloid leukemia

Occasional evolution—not inevitable malignant transformation.

Slide 39 · The immune and intrinsic models reinforce one another

From genetic injury to immunity

From immunity to clonal selection

Mutated stem cells may create new antigenic targets.

Immune pressure may preferentially eliminate susceptible clones.

T-cell surveillance may target these altered progenitors.

Residual populations can differ from the original stem-cell pool.

Slide 40 · Convergent mechanism of marrow aplasia

Two non-exclusive paths can converge on hematopoietic failure

Insult or inherited susceptibility

Immune-mediated injury

Stem-cell intrinsic injury

Activated T cells and IFN-γ inhibit and kill progenitors

Impaired genomic maintenance, clonality or replicative reserve

Aplasia and pancytopenia

Slide 41 · Mechanism predicts both reversibility and persistence

Some dose-related chemical suppression may reverse after exposure ends.

Persistent immune suppression can continue without a known initial trigger.

Intrinsic defects may restrict the capacity of remaining stem cells to recover.

Clinical outcome therefore depends on the underlying mechanism and residual marrow reserve.

Slide 42 · Mechanistic evidence: Observation versus inference

Observation

Hypocellular marrow; Apoptosis-gene expression; Clonal abnormalities.

Intervention

Improvement after T-cell–directed immunosuppression in a substantial subset.

Inference

Immune and stem-cell injury cooperate in at least some patients.

Mechanistic models integrate evidence; They do not replace patient-level diagnostic evaluation.

Slide 43 · Marrow morphology: Cellularity collapses

Schematic architecture - not a histopathology image

Hematopoietically active marrow

Aplastic marrow (marked hypocellularity)

Native editable conceptual schematic; Not representative of a clinical specimen.

Slide 44 · The marrow is dominated by nonhematopoietic elements

Hematopoietic precursors are markedly depleted.

Adipocytes occupy much of the biopsy space.

Fibrous stromal elements remain.

Scattered lymphocytes and plasma cells may still be present.

Slide 45 · Aspirate and trephine biopsy answer different questions

Aspirate

Core biopsy

May recover very little marrow material.

Directly shows the relationship of fat and residual cells.

“Dry tap” is a recognized practical problem.

Allows assessment of global hypocellularity.

A poor specimen cannot demonstrate architecture reliably.

Biopsy as central to diagnosis.

Slide 46 · The diagnostic morphology is hypoplasia

Marked depletion of marrow hematopoietic cells

The biopsy is usually the decisive evidence that pancytopenia reflects production failure.

Slide 47 · Why peripheral counts are reduced

Reduced functional stem-cell compartment

Fewer lineage-restricted progenitors

Reduced marrow cell production

Peripheral pancytopenia

The defect is inadequate supply, not simultaneous independent destruction of all three lineages.

Slide 48 · Peripheral tissues display secondary effects

Infection

Granulocytopenia predisposes to mucocutaneous bacterial infections.

Hemorrhage

Thrombocytopenia can produce abnormal bleeding and skin lesions.

Iron deposition

Multiple red-cell transfusions can be followed by systemic hemosiderosis.

Slide 49 · Anemia: Oxygen delivery becomes inadequate

Progressive weakness and fatigue reflect reduced red-cell mass.

Pallor reflects diminished circulating hemoglobin.

Dyspnea can develop as oxygen-delivery reserve falls.

The anemia may dominate early symptoms in some patients.

Slide 50 · Thrombocytopenia: Mucocutaneous bleeding pattern

Petechiae may be an early visible manifestation.

Ecchymoses are another characteristic cutaneous finding.

Platelet depletion explains the increased bleeding tendency.

Bleeding may bring patients to attention before anemia is pronounced.

Slide 51 · Neutropenia: Infection may be the first warning

Infections can become frequent or persistent.

A sudden fever with chills and severe prostration can occur.

The underlying deficit is ineffective granulocyte production.

Severe infection can dominate the presentation despite a slow marrow process.

Slide 52 · Blood morphology and reticulocyte response

Red-cell morphology

Reticulocytes

Cells are usually normochromic.

Reticulocytopenia is expected.

Slight macrocytosis may be present.

A low reticulocyte output demonstrates inadequate replacement.

Morphology alone is not diagnostic.

Interpret with the broader pancytopenia pattern.

Slide 53 · Reticulocytopenia is a production clue

Few young red cells are released because erythropoiesis is impaired

This finding helps localize the anemia to deficient marrow production rather than a compensatory marrow response.

Slide 54 · An important negative sign: No splenomegaly

Typical finding

Splenic enlargement is characteristically absent.

If enlarged

Reconsider whether aplastic anemia explains the entire syndrome.

Robbins explicitly advises questioning the diagnosis when splenomegaly is present.

Slide 55 · Clinical progression can be uneven

1

Stem-cell production capacity declines.

2

One lineage may cause the first symptoms.

3

Other cytopenias become clinically evident.

4

Pancytopenia defines the established syndrome.

The order of symptoms depends on the cell lineage affected most strongly.

Slide 56 · Repeated transfusions can produce hemosiderosis

Severe or persistent anemia

Repeated red-cell transfusions

Cumulative iron delivery

Systemic hemosiderosis

The iron deposition is a secondary treatment-associated consequence, not the primary cause of aplasia.

Slide 57 · Three clinicopathologic correlations

Weakness and pallor

Reduced erythroid progenitors → fewer red cells.

Petechiae and bruising

Reduced megakaryopoiesis → fewer platelets.

Persistent fever

Reduced granulopoiesis → impaired antimicrobial defence.

Slide 58 · Clinical application: A new pancytopenia

Hypothetical case: An adult develops weeks of weakness, bruising, and recurrent febrile infections. A blood count shows anemia, neutropenia, and thrombocytopenia.

Which unifying tissue-level process should be investigated?

Primary failure of hematopoietic cell production; Bone marrow core biopsy is central to assessment.

Slide 59 · Diagnostic logic in suspected aplastic anemia

Recognize pancytopenia

Document impaired red-cell output

Examine a marrow core biopsy

Interpret cellularity and exclude mimics

This is a teaching framework, not a formal decision rule or diagnostic severity classification.

Slide 60 · Marrow patterns help distinguish pancytopenias

Condition

Typical marrow pattern

Interpretive focus

Aplastic anemia

Marked hypocellularity

Depletion of all blood-forming elements

Myelodysplastic neoplasm

Usually hypercellular

Abnormal clonal hematopoietic precursors

Aleukemic leukemia

Neoplastic marrow involvement

Leukemia may be absent from peripheral blood

“Usually hypercellular” is the Robbins generalization; Exceptions require specialist assessment.

Slide 61 · Why leukemia can mimic marrow failure

Shared clinical manifestations

Key discriminating observation

Anemia, thrombocytopenia and neutropenia.

Examine the marrow directly.

Bleeding and infection may dominate.

Neoplastic progenitors support a myeloid neoplasm.

Peripheral blood can be misleading.

Marked paucity of all progenitors supports aplasia.

Slide 62 · Aplastic anemia versus myelodysplastic neoplasm

Aplastic anemia

Myelodysplastic neoplasm

Hematopoietic elements markedly depleted.

An alternative myeloid neoplastic cause of cytopenia.

Marrow is typically very hypocellular.

The typical marrow as hypercellular.

Intrinsic clonal injury can occur in a subset.

Occasional evolution from aplastic anemia is recognized.

Slide 63 · Pure red cell aplasia versus aplastic anemia

Feature

Aplastic anemia

Pure red cell aplasia

Affected marrow lineages

Multiple hematopoietic lineages

Selective erythroid progenitors

Peripheral blood pattern

Pancytopenia

Predominantly anemia

Marrow lesion

Marked generalized hypocellularity

Marked erythroid depletion

Important clinical context

Drugs, irradiation, immune injury, inherited defects

Thymoma, LGL leukemia, autoimmunity, parvovirus B19

Slide 64 · Pure red cell aplasia: Important associations

Thymoma

A well-established associated neoplasm.

Large granular lymphocytic leukemia

Another relevant hematolymphoid association.

Immune and viral conditions

Autoimmune disorders and parvovirus B19 may suppress erythroid cells.

Slide 65 · Parvovirus B19: Selective erythroid injury

Parvovirus B19 infection

Preferential infection of red-cell progenitors

Transient interruption of erythropoiesis

Possible aplastic crisis in hemolytic anemia

This is erythroid-selective suppression; It should not automatically be equated with global aplastic anemia.

Slide 66 · Why B19-related anemia depends on host context

Immunocompetent host

Most infections clear rapidly; Transient aplasia is often clinically minor.

Pre-existing hemolytic anemia

Brief loss of production can precipitate an aplastic crisis.

Severe immunosuppression

Persistent infection may cause chronic pure red cell aplasia.

Slide 67 · Clinical application: Selective red-cell failure

Hypothetical case: A patient with chronic hemolytic anemia develops sudden worsening of anemia during a parvovirus B19 infection, without a parallel decline in other blood-cell lineages.

Why is this not the classic presentation of global aplastic anemia?

B19 preferentially destroys erythroid progenitors; An aplastic crisis can reflect transient, lineage-selective failure.

Slide 68 · Two principal treatment strategies

Two non-exclusive paths can converge on hematopoietic failure

Clinically significant aplastic anemia

Stem-cell transplantation

Immunosuppressive therapy

Replace the failing marrow stem-cell compartment when an appropriate donor is available

Reduce the immune attack that inhibits residual marrow progenitors

Potential hematopoietic recovery

Slide 69 · Hematopoietic stem-cell transplantation

>75%

Five-year survival above 75% after transplantation in patients with a suitable donor.

The estimate is context-dependent and represents the textbook summary, not individualized prognosis.

Slide 70 · Why donor suitability matters

Transplantation aims to establish a functional hematopoietic stem-cell compartment.

Transplantation as the preferred option when a suitable donor is available.

Donor availability helps determine whether the transplant pathway is feasible.

Clinical decisions cannot be made from marrow morphology alone.

Slide 71 · Immunosuppression targets the extrinsic mechanism

Antithymocyte globulin / cyclosporine

Reduced T-cell–mediated marrow suppression

Survival of residual hematopoietic precursors

Partial or substantial marrow recovery

This approach as valuable, particularly without a suitable donor.

Slide 72 · Transplantation and immunosuppression act differently

Stem-cell transplantation

Immunosuppressive therapy

Replaces the compromised hematopoietic system.

Attempts to release remaining progenitors from immune suppression.

Requires an appropriate donor and clinical eligibility.

Does not directly replace the stem-cell pool.

May provide durable restoration of marrow function.

Can improve function in a substantial fraction of patients.

Slide 73 · Prognosis must remain individualized

Robbins characterizes the overall prognosis as variable.

Mechanism, severity of marrow failure and treatment feasibility all matter.

Clinical infection and bleeding complications arise from specific cytopenias.

Clonal evolution to a myeloid neoplasm is possible in a subset.

Slide 74 · Integrated clinicopathologic reasoning

Hypothetical case: A patient has pallor, petechiae, and recurrent bacterial infections. Blood testing confirms pancytopenia with a low reticulocyte count. Biopsy shows largely fatty marrow with few hematopoietic precursors.

Identify the syndrome, supporting morphologic feature, and key pathogenetic models.

Aplastic anemia; Markedly hypocellular marrow; Immune-mediated progenitor suppression and/or intrinsic stem-cell injury.

Slide 75 · Pitfalls that undermine the diagnosis

Pancytopenia alone

A low blood count does not establish aplastic marrow architecture.

Splenomegaly

Splenic enlargement should trigger reconsideration of the diagnosis.

Anemia alone

Isolated erythroid failure may represent pure red cell aplasia.

Slide 76 · Synthesis: Mechanism, morphology, clinical effects

Mechanism

Autoimmune T-cell injury and intrinsic stem-cell defects may coexist.

Morphology

Markedly hypocellular fatty marrow on core biopsy.

Clinical consequences

Reticulocytopenia, neutropenia and thrombocytopenia cause systemic symptoms.

Slide 77 · Diagnostic anchor

Pancytopenia + reticulocytopenia + hypocellular marrow

Assess exposures and inherited clues, exclude neoplastic mimics, and correlate treatment with the mechanism.

Slide 78 · Selected source and reading

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026).

Chapter 14, “Aplastic Anemia,” pages 599–601.

Related chapter sections: “Pure Red Cell Aplasia” (page 601) and “Paroxysmal Nocturnal Hemoglobinuria” (pages 589–590).

Textbook figures 14.23 and 14.24 are referenced conceptually; original figure plates were not supplied.